A2 Biotherapeutics Secures $80 Million Financing Round
A2 Biotherapeutics, Inc. (A2 Bio), a pioneering company in the field of cell therapies, recently announced the successful completion of an $80 million Series C financing round. This funding round saw support from prominent investors, enhancing the company’s capacity to advance its innovative precision therapies targeting solid tumors. The investment will primarily fuel the clinical development of their CAR-T cell therapies, which are built on their proprietary Tmod™ technology platform.
Investors and Funding Purpose
The financing was bolstered by a syndicate that includes esteemed firms such as The Column Group and Samsara BioCapital. The infusion of funds comes at a crucial time for A2 Bio as they are working toward the progression of three key clinical development programs that hold promise for patients with significant unmet medical needs across several types of cancer. Jim Robinson, the CEO, expressed excitement over initial clinical findings that underscore the efficacy of their unique logic-gated approach to cancer therapies.
Overview of Clinical Studies
A2 Bio is engaged in two pivotal clinical trials at this moment: EVEREST-1 and EVEREST-2. The EVEREST-1 study is focused on A2B530, which targets carcinoembryonic antigen (CEA) for pancreatic, lung, and colorectal cancers. Meanwhile, EVEREST-2 aims to study A2B694, targeting mesothelin (MSLN) in patients with pancreatic, ovarian, lung, colorectal, and mesothelioma cancers. Patient enrollment is being facilitated through BASECAMP-1, a prescreening study that leverages artificial intelligence to streamline the identification of candidates eligible for various A2 Bio clinical trials.
The Promise of Tmod™ Technology
The Tmod™ platform represents a groundbreaking advancement in targeting cancerous cells without harming normal tissue. By utilizing both an activator and a blocker receptor, this innovative technology empowers T cells to differentiate between tumor cells and healthy cells. The activator receptor identifies specific tumor antigens for destruction, while the blocker receptor ensures that normal cells are shielded from collateral damage. This dual mechanism enhances the precision of immune responses and improves treatment outcomes for cancer patients.
About A2 Biotherapeutics
Founded in 2018, A2 Biotherapeutics is on a mission to transform cancer treatment through the development of cutting-edge therapies that address substantial unmet medical needs. The company has positioned itself at the forefront of cell therapy innovation, harnessing their unique Tmod™ platform to overcome traditional challenges associated with cancer therapies, particularly the accurate targeting of malignant versus normal cells. As they continue to expand their pipeline, A2 Bio is committed to leveraging the recent financing to propel their studies forward.
Frequently Asked Questions
What is A2 Biotherapeutics known for?
A2 Biotherapeutics specializes in developing precision cell therapies, particularly targeting tumor cells while sparing normal cells.
What is the purpose of the $80 million financing?
The financing aims to support clinical development programs and enhance A2 Bio's pipeline of CAR-T cell therapies using their Tmod™ platform.
What clinical studies is A2 Bio currently conducting?
A2 Bio is conducting two key trials: EVEREST-1, targeting CEA for several cancers, and EVEREST-2, focusing on MSLN for multiple cancer types.
How does the Tmod™ platform work?
The Tmod™ platform employs a dual-receptor system, combining an activator for tumor cell recognition and a blocker for protecting normal cells.
When was A2 Biotherapeutics founded?
A2 Biotherapeutics was founded in 2018 and has quickly established itself as an innovator in the cell therapy landscape.
